Identification of human papillomavirus-16 E6 variation in cervical cancer and their impact on T and B cell epitopes

Journal of Virological Methods

Volumn 218, Issue , 2015, Pages 51-58

  Kumar, Anoop ^a,d   Hussain, Showket ^a   Yadav, Inderjit Singh ^b   Gissmann, Lutz ^c   Natarajan, K ^d   Das, Bhudev C ^d,e   Bharadwaj, Mausumi ^a  

^a INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

^b PUNJAB AGRICULTURAL UNIVERSITY   (India)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF DELHI   (India)

^e AMITY UNIVERSITY   (India)

Author keywords

Epitope; HPV; HPV variants; MHC alleles

Indexed keywords

EPITOPE; PROTEIN E6; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; HLA ANTIGEN CLASS 1; HLA DQ ANTIGEN; HLA-DQA1 ANTIGEN; HLA-DQB1 ANTIGEN; ONCOPROTEIN; REPRESSOR PROTEIN; VIRUS DNA;

AMINO ACID SEQUENCE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; E6 GENE; FEMALE; GENE IDENTIFICATION; GENETIC VARIABILITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOGENICITY; INDIAN; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; T LYMPHOCYTE; UTERINE CERVIX CANCER; CLASSIFICATION; DISEASE COURSE; DNA SEQUENCE; GENETICS; IMMUNOLOGY; INDIA; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX TUMOR; VIROLOGY;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16;

AMINO ACID SEQUENCE; BASE SEQUENCE; DISEASE PROGRESSION; DNA, VIRAL; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-DQ ALPHA-CHAINS; HLA-DQ BETA-CHAINS; HUMAN PAPILLOMAVIRUS 16; HUMANS; INDIA; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PHYLOGENY; REPRESSOR PROTEINS; SEQUENCE ANALYSIS, DNA; UTERINE CERVICAL NEOPLASMS;

EID: 84931750120     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2015.03.008     Document Type: Article

References (40)

1. Ashkenazy H., Erez E., Martz E., Pupko T., Ben-Tal N. ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic Acids Res. 2010, 38:W529-W533.
2. Baseman J.G., Koutsky L.A. The epidemiology of human papillomavirus infections. J. Clin. Virol. 2005, 32(Suppl. 1):S16-S24.
3. Bhattacharjee B., Mandal N.R., Roy S., Sengupta S. Characterization of sequence variations within HPV16 isolates among Indian women: prediction of causal role of rare non-synonymous variations within intact isolates in cervical cancer pathogenesis. Virology 2008, 377:143-150.
4. Bian H., Reidhaar-Olson J.F., Hammer J. The use of bioinformatics for identifying class II-restricted T-cell epitopes. Methods 2003, 29:299-309.
5. Buchan D.W., Minneci F., Nugent T.C., Bryson K., Jones D.T. Scalable web services for the PSIPRED protein analysis workbench. Nucleic Acids Res. 2013, 41:W349-W357.
6. Burd E.M. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev. 2003, 16:1-17.
7. Chen C.C., Hwang J.K., Yang J.M. (PS)2: protein structure prediction server. Nucleic Acids Res. 2006, 34:W152-W157.
8. Cohen T., Moise L., Ardito M., Martin W., De Groot A.S. A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: individualized T cell epitope measure (iTEM). J. Biomed. Biotechnol. 2010, 2010.
9. Das B.C., Sharma J.K., Gopalkrishna V., Das D.K., Singh V., Gissmann L., zur H.H., Luthra U.K. A high frequency of human papillomavirus DNA sequences in cervical carcinomas of Indian women as revealed by Southern blot hybridization and polymerase chain reaction. J. Med. Virol. 1992, 36:239-245.
10. de Villiers E.M. Human pathogenic papillomavirus types: an update. Curr. Top. Microbiol. Immunol. 1994, 186:1-12.
11. Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S., Markowitz L.E. Prevalence of HPV infection among females in the United States. JAMA 2007, 297:813-819.
12. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 2013, International Agency for Research on Cancer, Lyon, France, (Internet).
13. Getzoff E.D., Tainer J.A., Lerner R.A., Geysen H.M. The chemistry and mechanism of antibody binding to protein antigens. Adv. Immunol. 1988, 43:1-98.
14. Gokhale P.S., Sonawani A., Idicula-Thomas S., Kerkar S., Tongaonkar H., Mania-Pramanik J. HPV16 E6 variants: frequency, association with HPV types and in silico analysis of the identified novel variants. J. Med. Virol. 2014, 86:968-974.
15. Ho L., Chan S.Y., Chow V., Chong T., Tay S.K., Villa L.L., Bernard H.U. Sequence variants of human papillomavirus type 16 in clinical samples permit verification and extension of epidemiological studies and construction of a phylogenetic tree. J. Clin. Microbiol. 1991, 29:1765-1772.
16. Hung C.F., Ma B., Monie A., Tsen S.W., Wu T.C. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin. Biol. Ther. 2008, 8:421-439.
17. Igietseme J.U., Eko F.O., He Q., Black C.M. Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev. Vaccines 2004, 3:23-34.
18. Kohaar I., Hussain S., Thakur N., Tiwari P., Nasare V., Batra S., Singh V., Bhambani S., Das B.C., Sarkar D.P., Bharadwaj M. Association between human leukocyte antigen class II alleles and human papillomavirus-mediated cervical cancer in Indian women. Hum. Immunol. 2009, 70:222-229.
19. Li B., Wang Y., Chen J., Wu H., Chen W. Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587. Clin. Exp. Immunol. 2005, 140:310-319.
20. Lichtig H., Algrisi M., Botzer L.E., Abadi T., Verbitzky Y., Jackman A., Tommasino M., Zehbe I., Sherman L. HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6. Virology 2006, 350:216-227.
21. Londesborough P., Ho L., Terry G., Cuzick J., Wheeler C., Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int. J. Cancer 1996, 69:364-368.
22. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur. J. Cancer 2005, 41:2449-2461.
23. Mohabatkar H. Prediction of epitopes and structural properties of Iranian HPV-16 E6 by bioinformatics methods. Asian Pac. J. Cancer Prev. 2007, 8:602-606.
24. Munoz N., Bosch F.X., de S.S., Herrero R., Castellsague X., Shah K.V., Snijders P.J., Meijer C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348:518-527.
25. Pande S., Jain N., Prusty B.K., Bhambhani S., Gupta S., Sharma R., Batra S., Das B.C. Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in north India. J. Clin. Microbiol. 2008, 46:1060-1066.
26. Peng S., Trimble C., Ji H., He L., Tsai Y.C., Macaes B., Hung C.F., Wu T.C. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies. J. Biomed. Sci. 2005, 12:689-700.
27. Pillai M.R., Hariharan R., Babu J.M., Lakshmi S., Chiplunkar S.V., Patkar M., Tongaonkar H., Dinshaw K., Jayshree R.S., Reddy B.K., Siddiqui M., Roychoudury S., Saha B., Abraham P., Gnanamony M., Peedicayil A., Subhashini J., Ram T.S., Dey B., Sharma C., Jain S.K., Singh N. Molecular variants of HPV-16 associated with cervical cancer in Indian population. Int. J. Cancer 2009, 125:91-103.
28. Saha S., Raghava G.P. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins 2006, 65:40-48.
29. Saiki R.K., Gelfand D.H., Stoffel S., Scharf S.J., Higuchi R., Horn G.T., Mullis K.B., Erlich H.A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988, 239:487-491.
30. Sambrook Ra. Molecular Cloninig: A laboratory Manual 2001, Cold Spring Harbor Laboratory Press, 3.
31. Sellers W.R., Kaelin W.G. Role of the retinoblastoma protein in the pathogenesis of human cancer. J. Clin. Oncol. 1997, 15:3301-3312.
32. Singh A.K., Rath S.K., Misra K. Identification of epitopes in Indian human papilloma virus 16 E6: a bioinformatics approach. J. Virol. Methods 2011, 177:26-30.
33. Stoppler M.C., Ching K., Stoppler H., Clancy K., Schlegel R., Icenogle J. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J. Virol. 1996, 70:6987-6993.
34. Tamura K., Peterson D., Peterson N., Stecher G., Nei M., Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 2011, 28:2731-2739.
35. Tong J.C., Ren E.C. Immunoinformatics: current trends and future directions. Drug Discov. Today 2009, 14:684-689.
36. Tornesello M.L., Duraturo M.L., Buonaguro L., Vallefuoco G., Piccoli R., Palmieri S., Buonaguro F.M. Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy. Infect. Agent Cancer 2007, 2:1.
37. Yamada T., Manos M.M., Peto J., Greer C.E., Munoz N., Bosch F.X., Wheeler C.M. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J. Virol. 1997, 71:2463-2472.
38. Yao Y., Huang W., Yang X., Sun W., Liu X., Cun W., Ma Y. HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: an in silico approach. Vaccine 2013, 31:2289-2294.
39. Zehbe I., Voglino G., Wilander E., Genta F., Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 1999, 354:218-219.
40. zur H.H., de Villiers E.M. Human papillomaviruses. Annu. Rev. Microbiol. 1994, 48:427-447.